Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).
Miklos Pless(Ontario Institute for Cancer Research), Daniel Rauch(Washington University in St. Louis), Rolf A. Stahel(International Breast Cancer Study Group), Alexandros Xyrafas(Swiss Group For Clinical Cancer Research), Adrian F. Ochsenbein(University of Bern), Sandra Thierstein(Swiss Group For Clinical Cancer Research), Richard Cathomas(Kantonsspital Graubünden), M. Frueh(Kantonsspital St. Gallen), Roger Stupp(Northwestern University), Milorad Bijelović(Institute for Pulmonary Diseases of Vojvodina), Solange Peters(University Hospital of Lausanne), Alfred Zippelius(University of Basel), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Walter Weder(Krankenhaus Bethanien), Christoph Mamot(Kantonsspital Aarau), Urs R. Meier(Kantonsspital Winterthur), Hans‐Beat Ris(Centre Hospitalier Universitaire Vaudois), Arnaud Roth(Hôpital Beau-Séjour), Daniel Betticher, René‐Olivier Mirimanoff(University of Lausanne)
Cited by 19
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k